Company: LENZ
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001815776-25-000071
Chunk: 353

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 353
---
676 common stock warrants of the Company at an exercise price of $10.64, and were subsequently reclassified to stockholders’ equity at their fair value of $1.9 million.Share-Based CompensationShare-based compensation expense was as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Selling, general and administrative$3,207 $1,215 $7,228 $3,203 Research and development262 976 1,641 1,532 Total$3,469 $2,191 $8,869 $4,735 

8.     Net Loss Per Share

The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss 

21

per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:September 30,20252024Common stock options granted and outstanding3,823,0972,934,916Warrants to purchase common stock164,252164,676Restricted stock units granted and outstanding27,640—ESPP shares to be purchased18,694—Total4,033,6833,099,592

9.     License Agreements

CORXEL License and Collaboration AgreementIn April 2022, the Company entered into a license and collaboration agreement providing an exclusive license (the “CORXEL License,” formerly referred to as the “Ji Xing License”) to certain of the Company’s intellectual property (“IP”) for use in the treatment of presbyopia in humans in mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, and Taiwan (collectively, “Greater China”). The Company also agreed to a separate agreement for the purchase of clinical and commercial supply of products containing the IP for clinical and commercial requirements at cost plus a negotiated percentage and granted a right of first negotiation to obtain a regional license on other products the Company might develop outside the field of presbyopia for commercialization in Greater China.The Company received nonrefundable, non-creditable upfront payments totaling $15.0 million as